Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fate Therapeutics (FATE) Total Non-Current Liabilities (2016 - 2025)

Historic Total Non-Current Liabilities for Fate Therapeutics (FATE) over the last 14 years, with Q3 2025 value amounting to $103.0 million.

  • Fate Therapeutics' Total Non-Current Liabilities fell 2118.45% to $103.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $103.0 million, marking a year-over-year decrease of 2118.45%. This contributed to the annual value of $116.9 million for FY2024, which is 1433.16% down from last year.
  • Latest data reveals that Fate Therapeutics reported Total Non-Current Liabilities of $103.0 million as of Q3 2025, which was down 2118.45% from $104.7 million recorded in Q2 2025.
  • Over the past 5 years, Fate Therapeutics' Total Non-Current Liabilities peaked at $250.7 million during Q2 2021, and registered a low of $103.0 million during Q3 2025.
  • In the last 5 years, Fate Therapeutics' Total Non-Current Liabilities had a median value of $145.3 million in 2023 and averaged $169.1 million.
  • Its Total Non-Current Liabilities has fluctuated over the past 5 years, first skyrocketed by 14046.07% in 2021, then plummeted by 3733.77% in 2023.
  • Fate Therapeutics' Total Non-Current Liabilities (Quarter) stood at $218.4 million in 2021, then decreased by 0.31% to $217.8 million in 2022, then tumbled by 37.34% to $136.5 million in 2023, then dropped by 14.33% to $116.9 million in 2024, then dropped by 11.88% to $103.0 million in 2025.
  • Its last three reported values are $103.0 million in Q3 2025, $104.7 million for Q2 2025, and $105.2 million during Q1 2025.